A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.

Also called NCT07700875

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 391 participants (enrolled count) (from the registry)
Sponsor
Wuhan Createrna Science and Technology Co., Ltd (from the registry)
Registry
  • NCT NCT07700875
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07700875. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2023-08-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
QR12000 Compound Tablets 75 mg
Intervention (Drug)
QR12000 Compound Tablets 75 mg placebo
Intervention (Drug)
QR12000 Compound Tablets 150 mg
Intervention (Drug)
QR12000 Compound Tablets 150 mg placebo
Intervention (Drug)
QR01019 potassium salt 50 mg
Intervention (Drug)
QR01019 potassium salt 50 mg placebo
Intervention (Drug)
Sacubitril / valsartan 200 mg
Intervention (Drug)
Sacubitril / valsartan 200 mg placebo
Intervention (Drug)
Valsartan 160 mg
Intervention (Drug)
Valsartan 160 mg placebo
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07700875
Content hash
2cdbb192fddf4d21050d2ce60b5b459b29934580cb0738270ce231f1b9fae8ef